← boardnext 2027-07next 2027-10
ALVO
Alvotech Swiss AGdistress 3/10 · well-funded / low risk$3.23+1%today-67% from 52w high
alvotech.com1,279 employeesFounded 2013Luxembourg, LuxembourgDrug Manufacturers - Specialty & Generic
Immunology / Inflammation 1
Lead: Melanoma · est. market ~$10B (approx, global)
Revenue
$106M
Liquidity
$68M
Runway
1.4 yrs
Shares 1y
0%
Price & events
-37.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
+1.4%
1D
-4.0%
1W
-12.6%
1M
-4.3%
3M
-38.5%
6M
-64.7%
1Y
-72.6%
2Y
—
5Y
-71.1%
All
Overview
- Market Cap
- $1.01B
- Enterprise Value
- $2.21B
- Volume
- 26.37K
- 52 Week Range
- $3.00 – $9.81
- Total Shares
- 312.02M
- Float Shares
- 123.17M
- Short %
- 2.06%
- % Held by Insiders
- 54.54%
- % Held by Institutions
- 5.11%
- RVOL
- 0.03x
- Beta
- 0.19
Pipeline stages · 4 programs
AVT29 (proposed aflibercept HD biosimilar), Eylea HD (aflibercept HD)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
AVT32-DRL_PB, Keytruda
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
AVT16, Vedolizumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
AVT80, Geographical region 1 Entyvio, Geographical region 2 Entyvio
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-07 Estimated 50% readout ~2027-09-14 | Phase 3 | AVT29 (proposed aflibercept HD biosimilar), Eylea HD (aflibercept HD) | Diabetic Macular Edema | — | recruiting |
| 2027-10 Estimated 50% readout ~2027-10-31 | Phase 1 | AVT32-DRL_PB, Keytruda | Melanoma | — | not yet recruiting |
| 2026-01-08 | Phase 1 | AVT80, Geographical region 1 Entyvio, Geographical region 2 Entyvio | Healthy Male and Female Subjects | 385 | completed |
| 2025-11-25 | Phase 3 | AVT16, Vedolizumab | Ulcerative Colitis | 301 | terminated |
Catalyst news & presentations · 1
- 2026-08-19earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 312,021,375 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $15 (+351% upside) · 5 analysts
- 2026-03-24UBSBuy
- 2026-03-24BarclaysUnderweight
- 2025-12-09BarclaysUnderweight
- 2025-11-18UBSBuy
- 2025-11-04Deutsche BankBuy → Hold
- 2025-10-14Morgan StanleyEqual-Weight → Overweight
Competitors — Melanoma
- NVSEFNOVARTIS AG$292.0B · D3
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- IDYAIDEAYA Biosciences, Inc.$3.0B · D3
- IOVAIOVANCE BIOTHERAPEUTICS, INC.$2.3B · D4
- IMCRImmunocore Holdings plc$1.8B · D1
- REPLReplimune Group, Inc.$906M · D2
- AURAAura Biosciences, Inc.$722M · D6
- CATXPerspective Therapeutics, Inc.$334M · D5
- PHIOPhio Pharmaceuticals Corp.$12M · D7
- IOBTQIO Biotech, Inc.$71,949 · D5
Recent news
- 2026-07-22Alvotech (NASDAQ:ALVO) Slides as Market Concerns Deepen - Kalkine Media
- 2026-07-22Alvotech (NASDAQ:ALVO) Stock Price Down 7.8% - Here's What Happened - MarketBeat
- 2026-07-22Alvotech (ALVO) Q4 2024 Earnings Report - Results, Call & Slides - TipRanks
- 2026-07-21Inspection Findings Highlight Hurdles Facing Alvotech’s Launch Plans - insights.citeline.com
- 2026-07-19Alvotech files automatic mixed securities shelf - MSN
- 2026-07-17Novo, Alvotech face continued scrutiny at plants tied to recent FDA rejections - Fierce Pharma
- 2026-07-15Alvotech (ALVO) Could Be 76% Below Fair Value On New $75 Million Debt Facility - simplywall.st
- 2026-07-14Alvotech (NASDAQ:ALVO) Shares Down 5.5% - Here's What Happened - MarketBeat
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.